SEC Form 4 · accession 0001209191-19-002675
Verrica Pharmaceuticals Inc. · VRCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean Stalfort
Director
Period of report
Jan 7, 2019
Accepted (ET)
Jan 7, 2019 · 8:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660334
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 7, 2019 | P | 8,021 | $10.38 | A | 429,660 | D | |
| Common StockF2 | Jan 7, 2019 | P | 1,200 | $10.94 | A | 430,860 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $9.90 to $10.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $10.91 to $11.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.